Carmustine 100mg powder and solvent for solution for infusion vials
Requires a prescription from a doctor or prescriber
A cell-cycle phase nonspecific alkylating antineoplastic agent.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Carmustine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Carmustine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Carmustine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
8 branded products available
MHRA licensed products
View all licensed products for Carmustine on the MHRA register
Carmustine 100mg powder and solvent for concentrate for solution for infusion vials
Carmustine 100mg powder and solvent for concentrate for solution for infusion vials
Carmustine 100mg powder and solvent for concentrate for solution for infusion vials
Carmustine 100mg powder and solvent for concentrate for solution for infusion vials
Carmustine 100mg powder and solvent for solution for infusion vials
BiCNU 100mg powder and solvent for solution for infusion vials
Bristol-Myers Squibb Pharmaceuticals Ltd
Carmustine Obvius 100mg powder and solvent for concentrate for solution for infusion vials
Therapeutically similar medicines
Tablets & capsules
(3)Injectables
(1)Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(8)
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)
Brain tumours (primary) and brain metastases in over 16s (NG99)
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 18 · Randomised trials: 5 · 1982–2026
Showing the 50 most relevant studies, sorted by most relevant.
M. J. van den Bent, A. Brandes, R. Rampling, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009
R. Selker, W. Shapiro, P. Burger, et al.
Neurosurgery, 2002
S. Chowdhary, T. Ryken, H. Newton
Journal of Neuro-Oncology, 2015
Ran Wu, Liyuan Ma
Cell Transplantation, 2023
Rahimi SM, Bagheri A
2026
- Brain Neoplasms
- Carmustine
- RNA, Untranslated
J. Vose, Shelly L. Carter, L. Burns, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013
A. Fleming, W. Saltzman
Clinical Pharmacokinetics, 2002
M. Westphal, D. Hilt, E. Bortey, et al.
Neuro-oncology, 2003
L. Souhami, W. Seiferheld, D. Brachman, et al.
International journal of radiation oncology, biology, physics, 2004
S. Green, D. Byar, M. Walker, et al.
Cancer treatment reports, 1983
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
15-30 minutes
Mechanism
Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA s…
Food interactions
1 warning
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
5 to 28%
Half-life
15-30 minutes
Protein binding
80%
Metabolism
Elimination
60%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1387 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
ATC L01AD01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Carmustine
Additional database identifiers
Drugs Product Database (DPD)
2418
ChemSpider
2480
BindingDB
50015950
ZINC
ZINC000003830387
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4623
GenAtlas
GSR
GeneCards
GSR
GenBank Gene Database
X15722
GenBank Protein Database
31825
UniProt Accession
GSHR_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72